Contineum Therapeutics (CTNM) PT Raised to $32 at RBC Capital
RBC Capital analyst Brian Abrahams raised the price target on Contineum Therapeutics (NASDAQ: CTNM) to $32.00 (from $30.00) while maintaining ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)